Claims for Patent: 7,741,269

Summary for Patent: 7,741,269

Title:	Exendins and exendin agonists for weight reduction and obesity
Abstract:	Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Inventor(s):	Young; Andrew A. (San Diego, CA), Bhavsar; Sunil (San Diego, CA), Gedulin; Bronislava (San Diego, CA)
Assignee:	Amylin Pharmaceuticals, Inc. (San Diego, CA)
Application Number:	10/895,909
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,741,269
Patent Claims:	1. A method for reducing body weight in a human in need thereof comprising identifying a human in need of a reduction in body weight, and administering to the human a therapeutically effective amount of an exendin-4 peptide comprising the amino acid sequence of SEQ ID NO: 2 to reduce body weight. 2. The method of claim 1, wherein the therapeutically effective amount is 10 .mu.g per day to 1 mg per day. 3. The method of claim 1, wherein the therapeutically effective amount is 0.1 .mu.g/kg/day to 10 .mu.g/kg/day. 4. The method of claim 1, comprising parenterally administering the exendin-4 peptide. 5. The method of claim 1, comprising administering the exendin-4 peptide by peripheral injection. 6. The method of claim 1, wherein administration is intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical, transmucosal, transdermal, nasal, or pulmonary inhalation. 7. The method of claim 1, further comprising administering a therapeutically effective amount of an amylin, an amylin agonist, a leptin, a calcitonin, a cholecystokinin, or a combination of two or more thereof. 8. The method of claim 1, further comprising administering a therapeutically effective amount of pramlintide. 9. The method of claim 1, further comprising administering a therapeutically effective amount of at least one additional compound that is used to reduce body weight. 10. A method for reducing body weight in a human in need thereof comprising identifying a human in need of a reduction in body, and administering to the human a therapeutically effective amount of an exendin peptide or an exendin agonist analog peptide to reduce body weight. 11. The method of claim 10, wherein the exendin peptide or the exendin agonist analog peptide comprises the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2. 12. The method of claim 10, wherein the exendin peptide or the exendin agonist analog peptide comprises the amino acid sequence of SEQ ID NO:3, 4, or 5. 13. The method of claim 10, wherein the exendin peptide or the exendin agonist analog peptide comprises the amino acid sequence of SEQ ID NO:6, 7, 8, 9, 40, or 41. 14. The method of claim 10, wherein the exendin peptide or the exendin agonist analog peptide comprises the amino acid sequence of any one of SEQ ID NOs:10-39 and 42-188. 15. The method of claim 10, wherein the therapeutically effective amount is 10 .mu.g per day to 5 mg per day. 16. The method of claim 10, wherein the therapeutically effective amount is human 0.1 .mu.g/kg/day to 100 .mu.g/kg/day. 17. The method of claim 10, comprising administering the exendin peptide or the exendin agonist analog peptide by peripheral injection. 18. The method of claim 10, wherein administration is intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical, transmucosal, transdermal, nasal, or pulmonary inhalation. 19. The method of claim 10, further comprising administering a therapeutically effective amount of an amylin, an amylin agonist, a leptin, a calcitonin, a cholecystokinin, or a combination of two or more thereof. 20. The method of claim 10, further comprising administering a therapeutically effective amount of pramlintide. 21. The method of claim 10, further comprising administering a therapeutically effective amount of at least one additional compound that is used to reduce body weight. 22. A method for treating obesity in a human in need thereof comprising identifying a human in need of treatment for obesity, and administering to the human a therapeutically effective amount of an exendin-4 peptide comprising the amino acid sequence of SEQ ID NO: 2 to treat obesity. 23. The method of claim 22, wherein the therapeutically effective amount is 10 .mu.g per day to 1 mg per day. 24. The method of claim 22, wherein the therapeutically effective amount is 0.1 .mu.g/kg/day to 10 .mu.g/kg/day. 25. The method of claim 22, comprising parenterally administering the exendin-4 peptide. 26. The method of claim 22, comprising administering the exendin-4 peptide by peripheral injection. 27. The method of claim 22, wherein administration is intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical, transmucosal, transdermal, nasal, or pulmonary inhalation. 28. The method of claim 22, further comprising administering a therapeutically effective amount of an amylin, an amylin agonist, a leptin, a calcitonin, a cholecystokinin, or a combination of two or more thereof. 29. The method of claim 22, further comprising administering a therapeutically effective amount of pramlintide. 30. The method of claim 22, further comprising administering a therapeutically effective amount of at least one additional compound that is used to reduce body weight. 31. A method for treating obesity in a human in need thereof comprising identifying a human in need of treatment for obesity, and administering to the human a therapeutically effective amount of an exendin peptide or an exendin agonist analog peptide to treat obesity. 32. The method of claim 31, wherein the exendin peptide or the exendin agonist analog peptide comprises the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2. 33. The method of claim 31, wherein the exendin peptide or the exendin agonist analog peptide comprises the amino acid sequence of SEQ ID NO:3, 4, or 5. 34. The method of claim 31, wherein the exendin peptide or the exendin agonist analog peptide comprises the amino acid sequence of SEQ ID NO:6, 7, 8, 9, 40, or 41. 35. The method of claim 31, wherein the exendin peptide or the exendin agonist analog peptide comprises the amino acid sequence of any one of SEQ ID NOs:10-39 and 42-188. 36. The method of claim 31, wherein the therapeutically effective amount is 10 .mu.g per day to 5 mg per day. 37. The method of claim 31, wherein the therapeutically effective amount is human 0.1 .mu.g/kg/day to 100 .mu.g/kg/day. 38. The method of claim 31, comprising administering the exendin peptide or the exendin agonist analog peptide by peripheral injection. 39. The method of claim 31, wherein administration is intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical, transmucosal, transdermal, nasal, or pulmonary inhalation. 40. The method of claim 31, further comprising administering a therapeutically effective amount of an amylin, an amylin agonist, a leptin, a calcitonin, a cholecystokinin, or a combination of two or more thereof. 41. The method of claim 31, further comprising administering a therapeutically effective amount of pramlintide. 42. The method of claim 31, further comprising administering a therapeutically effective amount of at least one additional compound that is used to reduce body weight. 43. A method for reducing body weight in a human in need thereof comprising identifying a human in need of a reduction in body weight, and subcutaneously administering to the human from 0.1 .mu.g/kg/day to 10 .mu.g/kg/day of an exendin-4 peptide comprising the amino acid sequence of SEQ ID NO: 2 to reduce body weight. 44. A method for treating obesity in a human in need thereof comprising identifying a human in need of treatment for obesity, and subcutaneously administering to the human from 0.1 .mu.g/kg/day to 10 .mu.g/kg/day of an exendin-4 peptide comprising the amino acid sequence of SEQ ID NO: 2 to treat obesity.